Nov 29, 2023 8:00 am EST MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%
Nov 21, 2023 10:42 am EST MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern Time
Nov 21, 2023 10:09 am EST MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1a
Nov 20, 2023 8:00 am EST MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
Sep 18, 2023 8:30 am EDT MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than Pot
Sep 05, 2023 8:31 am EDT MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication Efforts
Aug 31, 2023 8:31 am EDT MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development Summit
Aug 29, 2023 11:39 am EDT MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern Time
Aug 09, 2023 8:47 am EDT MIRA Pharmaceuticals to Ring the Nasdaq Opening Bell on Wednesday, August 9, 2023
Aug 02, 2023 6:44 pm EDT MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial Public Offering and Nasdaq Listing